Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease
about
Combined aclidinium bromide and long-acting beta 2 -agonist for COPDNanodiamonds: The intersection of nanotechnology, drug development, and personalized medicinePharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysisPositioning new pharmacotherapies for COPDClinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of lifeProfile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPDA review of nebulized drug delivery in COPDInhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment ParadigmIs aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease.β2 adrenergic agonist suppresses eosinophil-induced epithelial-to-mesenchymal transition of bronchial epithelial cellsReduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.Study Design of VESUTO®: Efficacy of Tiotropium/Olodaterol on Lung Hyperinflation, Exercise Capacity, and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease.Advances in device and formulation technologies for pulmonary drug delivery.Indacaterol inhibits tumor cell invasiveness and MMP-9 expression by suppressing IKK/NF-κB activation.The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPDProfile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.In Vitro, Pharmacokinetic, Pharmacodynamic, and Safety Comparisons of Single and Combined Administration of Tiotropium and Salmeterol in COPD Patients Using Different Dry Powder Inhalers.Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers.Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UKRole of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long-Acting β2 -Agonists and Inhaled Corticosteroids: The OUTPUL StudyKCNQ (Kv7) potassium channel activators as bronchodilators: combination with a β2-adrenergic agonist enhances relaxation of rat airways.New dual-acting bronchodilator treatments for COPD, muscarinic antagonists and β2 agonists in combination or combined into a single molecule.Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD.New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol.QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.Recent advances in COPD disease management with fixed-dose long-acting combination therapies.Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date
P2860
Q24187613-D5C4F8FE-B780-41FD-B9F9-A84B164A86BDQ26776095-800D68AF-3BFE-4ABF-BF78-DBC3B0A2E5EFQ26777927-BFF7C290-E016-4660-9263-0CBBB47067EDQ26782484-E775115C-B6F0-4EB4-B5D4-A7696DFD4BC1Q26798659-B4F7C977-A1D9-4D67-AC2D-ADAD526A75F7Q26801134-9220866B-816D-4A80-8378-FC33C0E1A2D1Q26825822-7ADC263E-B728-47D2-9A85-8B96B1DF827AQ28075295-0FB81729-6524-4507-8D3A-A755F21E3894Q28087788-C568E696-BE32-4675-A0DC-B0C1BEFC120CQ30365242-65948B5C-689A-4506-9FD9-9432CB5E89A7Q30397854-EEF4E498-0831-41A1-ADAB-68D77797A0DCQ33629810-6267C9D1-C783-4A9D-8C07-9BEF7033FF6DQ33743284-F8B4380E-C43E-4310-A196-EDA2E98F1F8AQ33783760-01940A98-BB9C-41CE-9F66-0CD6AC54A52EQ33838209-0A635EF6-6E77-4BE9-9344-2EF275AB2D86Q33890178-515197BE-712D-4160-B592-415062397ABBQ33890852-134A004C-BC9A-45C2-BEAA-D2F7E0788F3AQ33962567-C3CCBB24-FBCE-4F33-8A5C-A67DEE1DE753Q34092070-3176D3B0-C3EE-49D9-BAB4-1AB5D73FC3E1Q34368537-C5663C8A-A277-4F37-BB39-CA96DD5D101DQ34386867-C6EEC360-429D-42EA-801D-98B53E604DFBQ34753755-F3B45F21-2BD8-4177-AA04-3C6751DB049CQ35344118-844EBEC4-8D11-4A83-A9D0-478BB6F8BB9DQ35492192-B521B34F-3BBA-4C37-A859-B02EC20FE790Q35766346-7BD1C6D2-407A-405B-9DFE-4FA4D4AF6B02Q35768368-F8826129-ADA9-4E08-94D0-046D8CBE0716Q35936707-2DD2593C-D36C-463C-B21C-867D9A994CFBQ35937943-C6F81E2B-19FC-4109-99E7-46FFC1A52EA4Q36158846-F79E74F3-5A79-4378-A6F9-0F485CAA0D1DQ36366132-011B6FC3-9891-4719-9AA3-4E924B607EE8Q37418094-BADC05DA-E750-47A5-97A7-EB8AA353979AQ37629298-C1857C27-A16D-469C-BEF7-1C5558F95918Q38130337-FA7A5C54-FB72-4E94-95F2-D2F16BFF4FBCQ38137141-EC6FABD5-53BA-4985-8E81-CD77C76EB7D1Q38154255-E58D80CF-EA4D-464D-9AEC-4C5156E47D98Q38194114-D00DD1EB-AA00-4590-A60B-90560DA274E3Q38209841-9DF5C101-A00B-4A5C-A28C-BB044ECE601CQ38303157-B57FFB56-B326-4D84-BF2D-CAB48B91438DQ38371305-994D0DD6-4880-4622-B5EA-43D65FF395AAQ38432438-DCECDFA8-310E-4FF6-861A-0FB5A3A3E8EF
P2860
Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Combination bronchodilator the ...... obstructive pulmonary disease
@ast
Combination bronchodilator the ...... obstructive pulmonary disease
@en
Combination bronchodilator the ...... obstructive pulmonary disease
@nl
type
label
Combination bronchodilator the ...... obstructive pulmonary disease
@ast
Combination bronchodilator the ...... obstructive pulmonary disease
@en
Combination bronchodilator the ...... obstructive pulmonary disease
@nl
prefLabel
Combination bronchodilator the ...... obstructive pulmonary disease
@ast
Combination bronchodilator the ...... obstructive pulmonary disease
@en
Combination bronchodilator the ...... obstructive pulmonary disease
@nl
P2860
P3181
P356
P1433
P1476
Combination bronchodilator the ...... obstructive pulmonary disease
@en
P2093
Donald P Tashkin
Gary T Ferguson
P2860
P2888
P3181
P356
10.1186/1465-9921-14-49
P407
P577
2013-05-08T00:00:00Z
P5875
P6179
1051849337